Insulin glargine (glargine) and insulin NPH (NPH) are two basal insulin treatments.
When comparing the four groups, NPH patients had a significant greater aqueductal SV than the HEVs and AD patients.
Importantly, we did not observe a significant increase in cell proliferation in response to ROCKi as measured by the number of Hoechst-labeled nuclei across different conditions (DMSO: 522 ± 126; Fasudil 1 µM: 598 ± 21; Y0503 1 µM: 625 ± 88 cells/well, n = 3 in triplicate wells counting cells from three different Nph preparations).
In mapping NPH, two markers in the region had a combined RMIP of 0.60 but no marker with a RMIP >0.10 was found for DTA.
The RR estimate of all malignant breast tumour cases, including non-serious cases (three in the insulin glargine group vs five in the NPH insulin group) numerically favours insulin glargine (RR 0.59, 95% CI 0.14 2.44).
Graff-Radford and Godersky later found that three of 30 NPH patients had a head size at or above the 98th percentile [35], thus concluding that NPH occurred as a result of decompensation of arrested congenital hydrocephalus.
No participant on glargine and four participants on NPH insulin started prandial insulin during the study.
During the entire intervention period, eight patients in the NPH insulin group experienced eight episodes of severe hypoglycemia and 11 patients in the aspart group experienced 13 episodes.
The uses of NPH in three of these four studies (8, 10, 11) and regular insulin in one of the crossover studies (11) instead of the rapid- and long-acting analogs are also limiting factors for establishing a comparison between the MDI versus CSII regimens.
For NPH insulin, three patients, of whom two were excluded from the CBF analyses, required dextrose tablets because of a low or falling blood glucose level, whereas two patients, who were afterward excluded from the CBF analyses, received ∼15 mL i.v. 20% glucose before the PET scan started.
